Early Effects of a Pain-Informed Movement Program in Patients with Post-COVID-19 Condition Experiencing Persistent Pain: Protocol for a Randomized Controlled Trial.

Publication date: Jan 20, 2024

(1) Background: The COVID-19 pandemic has generated 771 million confirmed cases. Of these patients, 60% have developed persistent symptoms including pain. This pain is a complex symptom that needs comprehensive therapeutic strategies to address it holistically. The main objective of this study will be to evaluate the early impact of the Pain Informed Movement (PIM) program in patients with post-COVID-19 conditions experiencing new-onset persistent pain. (2) Methods: A randomized, single-blind clinical trial will be performed. Patients will be randomly assigned (1:1) to the experimental or control group. The experimental group will undergo a PIM program consisting of low-intensity functional exercises, pain neuroscience education, and relaxation techniques. The control group will receive no intervention. (3) Results: The results will be published as a peer-reviewed article. (4) Conclusions: This study will provide a basis for future research to support the implementation of comprehensive therapeutic approaches in the care of patients with post-COVID-19 persistent pain.

Open Access PDF

Concepts Keywords
Clinical intervention
Future persistent pain
Neuroscience post COVID-19 condition
Pandemic protocol
Randomized randomized control trial


Type Source Name
disease MESH COVID-19
disease VO protocol
disease IDO symptom
disease IDO intervention
disease VO frequency
drug DRUGBANK Hexocyclium
disease IDO process
disease MESH psychological distress
disease MESH sleep disorders
drug DRUGBANK Coenzyme M
disease MESH kinesiophobia
disease MESH Long COVID
disease VO organization
drug DRUGBANK Aspartame
disease MESH cognitive impairment
disease MESH reinfection
disease IDO history
disease MESH critical illness
disease MESH chronic pain
disease IDO site
disease IDO replication
disease VO time
disease VO population
disease VO efficient
drug DRUGBANK Oxygen
drug DRUGBANK Carbon dioxide
drug DRUGBANK Pentaerythritol tetranitrate
disease MESH infection
disease VO report
disease VO USA
disease VO effectiveness
drug DRUGBANK Trestolone
disease VO effective
disease MESH sarcopenia
disease MESH musculoskeletal pain
disease MESH osteoarthritis
disease MESH blindness
drug DRUGBANK Guanosine
drug DRUGBANK (S)-Des-Me-Ampa
disease MESH syndrome
disease MESH sequelae
disease MESH pneumonia
disease MESH Virus Infections
disease MESH Hypersensitivity
drug DRUGBANK D-Alanine
disease MESH knee osteoarthritis
disease MESH comorbidity
disease MESH prostate cancer
pathway KEGG Prostate cancer
disease MESH Cancer
disease MESH fibromyalgia
disease MESH Clinical Importance

Original Article

(Visited 1 times, 1 visits today)